Mr. Sorensen graduated from Duke University (B.A. magna cum laude 1983) and from Yale University (J.D. 1989).  He was Law Clerk to the Hon. Norma L. Shapiro (E.D. Pa.), in 1990-1991.  He is admitted to practice law in the Commonwealth of Pennsylvania, the United States Supreme Court, and numerous federal Courts of Appeal.

Mr. Sorensen practices in the areas of antitrust class actions and complex mass tort litigation.  He helped try a class action property damage case, Cook v. Rockwell Corp., that resulted in a jury verdict of $554 million on February 14, 2006, after a four-month trial, on behalf of thousands of property owners near the former Rocky Flats nuclear weapons plant located outside Denver, Colorado.  The verdict was the third-largest jury verdict of 2006 in the United States, according to The National Law Journal; the largest in Colorado history; and was the first time a jury had awarded damages to property owners living near one of the nation’s nuclear weapons sites.  In 2008, the District Court entered a $926 million judgment for plaintiffs.  In July 2009,  the trial team, including Mr. Sorensen, won the “Trial Lawyer of the Year” award from the Public Justice Foundation, for its work on the Cook case.

Mr. Sorensen played a major role in the firm’s representation of the State of Connecticut in State of Connecticut v. Philip Morris, Inc., et al., in which Connecticut recovered approximately $3.6 billion from certain tobacco companies.

Mr. Sorensen also has played major roles in a number of antitrust cases representing direct purchasers of prescription drugs.  These cases have alleged that pharmaceutical manufacturers have wrongfully kept less expensive generic drugs off of the market, in violation of federal antitrust laws.  Several of these cases have resulted in substantial cash settlements, including In re Terazosin Hydrochloride Antitrust Litigation, MDL 1317 (S.D. Fla.) ($74.5 million); and In re Remeron Antitrust Litig. (D.N.J.) ($75 million).  Mr. Sorensen also argued and won class certification in  In re K-Dur Antitrust Litigation, 2008 WL 2699390 (D.N.J. April 14, 2008), and In re Nifedipine Antitrust Litigation, 246 F.R.D. 365 (D.D.C. 2007); and argued and obtained a precedent-setting victory in In re DDAVP Direct Purchaser Antitrust Litigation, 585 F.3d 679 (2d Cir. 2009), in which the Second Circuit held that direct purchasers had standing to seek antitrust damages relating to Walker Process patent fraud.  Most recently, he argued on behalf of direct purchaser plaintiffs in King Drug Co. v. Cephalon, Inc., __ F. Supp. 2d __, 2010 WL 1221793 (E.D. Pa. March 29, 2010), in which the court denied defendants’ motions to dismiss antitrust claims arising from agreements between the drug company Cephalon and its generic competitors; agreements that, plaintiffs allege, have wrongfully blocked generic competition.
                        
Mr. Sorensen also is co-lead counsel in Johnson v. Arizona Hospital and Healthcare Assoc., No. CV 07-1292-PHX-SRB (D. Ariz.), representing a class of temporary nurses alleging they were underpaid as a result of price-fixing by numerous Arizona hospitals.

Mr. Sorensen presented at symposia in November 2004, and in September 2009, focusing on antitrust issues in the pharmaceutical industry, at the University of San Francisco School of Law, and co-authored, with one of the school’s law professors, Joshua P. Davis, Chimerical Class Conflicts in Federal Antitrust Litigation:  The Fox Guarding the Chicken House in Valley Drug, 39 U.S.F. Law Review 141 (Fall 2004).  

In October 2007, Mr. Sorensen, with Merrill G. Davidoff and Peter Nordberg, presented a series of symposia on complex litigation for all Pennsylvania Common Pleas judges (trial court).  He also has been a guest lecturer at the University of Colorado Law School.   

Mr. Sorensen has been named as one Pennsylvania’s “SuperLawyers,” every year since 2005 in Philadelphia Magazine; and has received the highest peer-review rating, “AV,” in Martindale-Hubbell.